论文部分内容阅读
目的探讨恩度联合吉西他滨、顺铂(GP)方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法回顾性分析40例经组织病理学证实的晚期(ⅢB/Ⅳ期)非小细胞肺癌患者的临床资料。40例初治患者均接受恩度联合GP方案的化疗。GP:吉西他滨1000mg/m2,第1、第8天,DDP 25mg/m2,第1～3天,每21天重复给药。同时给予恩度7.5mg/m2,每次用量15mg,静点4小时,第1～14天连续给药,间歇7天重复。2个周期后进行疗效评定,观察其疾病进展时间及不良反应。结果全部患者均接受2个周期以上化疗,共化疗142个周期。40例患者中CR为0例,PR为17例,SD为13例,PD为10例,客观有效率CR+PR(RR)为42.5%,疾病控制率为(CR+PR+SD)75.0%,中位疾病进展时间(mTTP)为11月。结论恩度联合GP方案治疗晚期非小细胞肺癌是一种安全、有效的治疗方法。不良反应轻,恢复快,患者耐受好。
Objective To investigate the clinical efficacy and adverse reactions of Endu combined with gemcitabine and cisplatin (GP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods The clinical data of 40 patients with advanced stage ⅢB / Ⅳ non-small cell lung cancer confirmed by histopathology were retrospectively analyzed. Forty patients with newly diagnosed patients underwent entecavir combined with GP regimen. GP: Gemcitabine 1000mg / m2, 1st, 8th day, DDP 25mg / m2, 1st to 3rd days, repeated every 21 days. At the same time give a degree of 7.5mg / m2, each dosage 15mg, static point 4 hours, 1 to 14 days of continuous administration, intermittent 7 days repeat. After 2 cycles of efficacy evaluation, observe the progress of the disease and adverse reactions. Results All patients received more than two cycles of chemotherapy, a total of 142 cycles of chemotherapy. Among the 40 patients, CR was 0, PR was 17, SD was 13, and PD was 10. The objective response rate was 42.5% for CR + PR and 75.0% for CR + PR + SD, , Median disease progression time (mTTP) for November. Conclusion Endood combined with GP regimen in the treatment of advanced non-small cell lung cancer is a safe and effective treatment. Adverse reactions, recover quickly, patients tolerate well.